Harvard Dana-Farber Cancer Institute’s ASH Highlights 2025
A focused hematology and oncology update designed to help clinicians review the most clinically relevant data presented at the ASH Annual Meeting, with practical updates in blood cancers, classical hematology, transplantation, cellular therapies, and emerging treatment strategies.
Course Details:
Harvard Dana-Farber Cancer Institute’s ASH Highlights 2025 is a recorded hematology and oncology course focused on new developments in the diagnosis and treatment of blood cancers and non-malignant hematologic disorders.
Focus: Acute leukemia, myelodysplastic syndromes, myeloproliferative neoplasms, chronic myelogenous leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, Waldenström’s macroglobulinemia, classical hematology, coagulation disorders, hematopoietic stem cell transplantation, and CAR-T cell therapy.
About This Course
The ASH Annual Meeting is one of the most important scientific events in hematology, where new research, emerging therapies, and practice-changing data are presented across malignant and non-malignant blood disorders.
This course brings together clinically relevant highlights from ASH in a concise, disease-specific format, helping hematologists, oncologists, and related clinicians identify the most important advances and understand how they may influence patient care.
The program focuses on practical translation of new data into professional practice, with updates across leukemia, lymphoma, plasma cell disorders, transplantation, CAR-T therapy, coagulation, and classical hematology.
Why Choose This Course
- Harvard Dana-Farber Cancer Institute ASH Highlights 2025 course
- Designed to summarize clinically relevant data presented at the ASH Annual Meeting
- Covers major blood cancers and important non-malignant hematology updates
- Includes disease-specific lectures across leukemia, lymphoma, myeloma, transplantation, CAR-T, and classical hematology
- Focused on emerging therapies, treatment approaches, and practical clinical application
- Useful for oncology and hematology physicians, trainees, primary care physicians, nurses, physician assistants, and nurse practitioners
- Recorded format allows flexible review of the key ASH highlights at your own pace
Core Learning Areas
Leukemia & Myeloid Disorders
Updates in ALL, AML, MDS, CML, and myeloproliferative neoplasms with emphasis on new data and evolving treatment strategies.
Lymphoid Malignancies
Clinically relevant advances in CLL, Hodgkin lymphoma, non-Hodgkin lymphoma, lymphoma treatment, and disease-specific management.
Myeloma & Plasma Cell Disorders
Key updates in multiple myeloma, Waldenström’s macroglobulinemia, treatment selection, and emerging therapeutic approaches.
Transplant, CAR-T & Classical Hematology
Hematopoietic stem cell transplantation, CAR-T therapy, coagulation disorders, and practical non-malignant hematology updates.
Complete Curriculum
- Overview of recent medical advances presented at the ASH Annual Meeting
- Clinically relevant updates for hematology and oncology practice
- Disease-specific review of emerging treatment strategies
- Translation of research findings into practical patient care
- Approach to incorporating new evidence into treatment planning
- Review of emerging therapies and evolving standards of care
- Improving patient outcomes through timely access to new hematology data
- ASH transplant highlights and major clinical updates
- Hematopoietic stem cell transplantation advances
- Patient selection and treatment strategy considerations
- New evidence affecting transplant decision-making
- Management issues related to transplant outcomes
- Integration of transplant data into hematologic malignancy care
- Practical review for clinicians involved in complex hematology care
- ASH highlights in acute lymphoblastic leukemia
- New and emerging treatment approaches in ALL
- Chronic myelogenous leukemia updates
- Myeloproliferative neoplasm highlights
- Clinical interpretation of new study data
- Therapeutic sequencing and treatment strategy considerations
- Applying ASH data to routine hematology practice
- ASH classical hematology updates
- New therapies and approaches in non-malignant hematology
- Coagulation disorder updates
- Clinical decision-making in complex blood disorders
- Practical interpretation of new classical hematology evidence
- Improving patient management using updated data
- Non-malignant hematology pearls for clinical practice
- Myelodysplastic syndrome highlights
- Acute myeloid leukemia updates from ASH
- Emerging treatment options in myeloid malignancies
- Risk stratification and therapeutic decision-making
- Interpreting new clinical trial data in MDS and AML
- Practical approaches to evolving treatment standards
- Clinical application of new evidence in leukemia care
- Chronic lymphocytic leukemia updates
- New data affecting CLL treatment strategies
- Approach to selecting therapies for CLL patients
- Emerging targeted therapies and treatment combinations
- Clinical interpretation of ASH CLL highlights
- Monitoring response and managing treatment-related issues
- Practical application of CLL updates in routine practice
- Multiple myeloma updates from ASH
- Emerging treatment strategies in plasma cell disorders
- New therapeutic approaches and clinical trial data
- Management considerations for relapsed and refractory disease
- Clinical interpretation of myeloma research highlights
- Integrating new therapies into patient-centered care
- Practical guidance for hematology and oncology clinicians
- Lymphoma updates presented at ASH
- Hodgkin lymphoma and non-Hodgkin lymphoma highlights
- Emerging treatments in lymphoid malignancies
- New evidence affecting treatment selection
- Clinical data relevant to common lymphoma subtypes
- Approach to applying ASH lymphoma updates in practice
- Practical disease-specific review for clinicians managing lymphoma patients
- CAR-T therapy updates from ASH
- Emerging cellular therapy data
- Clinical applications of CAR-T in hematologic malignancies
- Patient selection and treatment strategy considerations
- Safety, toxicity, and outcome considerations in cellular therapy
- Integration of CAR-T data into lymphoma, leukemia, and myeloma care
- Future directions in cellular therapy and immune-based treatment
- Updates in Waldenström’s macroglobulinemia
- Clinical interpretation of new plasma cell and lymphoplasmacytic disorder data
- Therapeutic considerations for rare hematologic malignancies
- Monitoring response and disease progression
- Practical management of complex blood cancer presentations
- Integrating emerging evidence into treatment planning
- Improving clinical confidence in less common hematologic disorders
Learning Objectives
- Describe key recent medical advances presented at the ASH Annual Meeting
- Recognize clinically relevant updates in the diagnosis and treatment of blood cancers
- Identify emerging treatments available for hematologic malignancies
- Apply updated approaches to routine clinical hematology and oncology practice
- Review treatment options for leukemia, lymphoma, myeloma, and related blood disorders
- Understand important advances in hematopoietic stem cell transplantation
- Review current CAR-T therapy highlights and their clinical implications
- Recognize new therapies and approaches in non-malignant hematology
- Interpret disease-specific ASH data and translate it into patient care
- Improve clinical decision-making for patients with hematologic disorders
Who Should Take This Course
This course is designed for oncology physicians, hematology physicians, hematology/oncology trainees, primary care physicians, nurses, physician assistants, nurse practitioners, and healthcare professionals involved in the care of patients with blood cancers and hematologic disorders.
It is especially useful for clinicians who want a concise and clinically relevant review of the most important ASH updates in leukemia, lymphoma, myeloma, transplantation, CAR-T therapy, coagulation disorders, and classical hematology.
Delivery & Access
Recorded Course
Review the ASH highlights content at your own pace.
2025 Edition
Focused review of clinically relevant hematology updates.
1-Day Program
Concise, disease-specific lectures covering major ASH highlights.
Support
Reviews
Dr. Sarah Thompson
Excellent overview of recent hematology advances with clinically useful takeaways for patient care.
Dr. Michael Chen
Strong faculty presentations and clear explanations of complex hematology and oncology updates.
Dr. Emily Patel
Well-organized course structure that makes the major ASH highlights easy to review and apply.
FAQ
Who is this course best suited for?
This course is best suited for oncology and hematology physicians and trainees, primary care physicians, nurses, physician assistants, nurse practitioners, and clinicians caring for patients with hematologic disorders.
What topics are covered?
Topics include acute leukemia, myelodysplasia, myeloproliferative disorders, chronic myelogenous leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, Waldenström’s macroglobulinemia, coagulation disorders, hematopoietic stem cell transplantation, classical hematology, and CAR-T therapy.
Is this course focused on ASH Annual Meeting updates?
Yes. The course is designed to highlight clinically relevant data and treatment updates presented at the ASH Annual Meeting.
Is this course practical for hematology and oncology practice?
Yes. The course focuses on disease-specific updates and emerging treatment approaches that can be applied in routine clinical practice.
Is this a recorded course?
Yes. This product is provided as recorded course access so you can review the material at your own pace.
Does this course include CME or a certificate?
No. CME credits and certificates are not included with this course package.
Who can I contact for support?
You can contact support at [email protected].
Dr. Sarah Thompson, Hematology –
This course provided an excellent overview of the latest advancements in hematology. Each session was packed with valuable insights!
Dr. Michael Chen, Oncology –
“The faculty were outstanding! Their expertise and ability to convey complex topics made the learning experience enjoyable.”
Dr. Emily Patel, Blood Disorders: –
“The structure of the course was logical and easy to follow, making it simple to grasp the key takeaways from each presentation.”
Dr. James Lee, Pediatric Hematology –
“Having the course recorded and available on Google Drive was a game-changer. I could revisit sessions at my convenience.”
Dr. Laura Kim, Clinical Research –
“I appreciated the focus on cutting-edge research and clinical applications. It’s crucial for staying updated in the field.”
Dr. Natalie Clark, Research Scientist –
“I would highly recommend this course to anyone in the oncology field. It’s a fantastic resource for professional development.”
Dr. Matthew Brown, Bone Marrow Transplant –
“I felt motivated after completing this course. The passion of the speakers was contagious!”
Dr. Julia Patel, Molecular Hematology –
“This course will serve as a great reference for my practice. The materials provided were comprehensive and well-curated.”
Dr. Angela Rivera, Blood Cancer Specialist –
“The discussions in the course allowed for networking with other professionals, which is invaluable in our field.”
Dr. David Wong, Adult Hematology –
“I found the practical applications of the research particularly helpful. It’s great to see theory translated into practice.”
Dr. Rachel Adams, Transfusion Medicine –
“The presenters did a fantastic job of breaking down complex information into digestible parts. I left feeling informed and inspired!”